TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean Change in Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Change in Pulse Oxymetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Change in the Conway Clinical Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self and peer assessment impressions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stoma care rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of novel PET tracer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: L. donovani infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pre-patent period onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of anatomic urethral stricture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence/absence of symptoms and abnormal laboratory findings
Endpoint domain: Adverse events/effects
Primary endpoint: Flicker induced increase in retinal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in functional gait performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exclusive breastfeeding (EBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversal of minimal hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Identification of Acute Coronary Syndromes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Days of Continuous Cocaine Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and Tolerability Assessments by Vital Signs
Endpoint domain: Adverse events/effects
Primary endpoint: Mean time to Itch Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Objective Response (Partial Response and Complete Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Clinical Dementia Rating (CDR) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with treatment-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Altered disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in non-HDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy in rehabilitative therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of FDG-PET imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Empathy score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Concentration (Cmax) of Mycophenolic Acid (MPA), Mycophenolic Acid Glucuronide (MPAG) and Acyl Glucuronide Metabolite of Mycophenolic Acid (AcMPAG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration (Tmax) of MPA, MPAG, AcMPAG and Free MPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time 0 to 12 Hours (AUC0-12) of MPA, MPAG and AcMPAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unprotected sexual acts
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients demonstrating clinical benefit from treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients experiencing Graft Versus Host Disease (GvHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Disseminated Intravascular Coagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Survival (OS) Rate at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Severe Immune-Mediated Adverse Reactions (imARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Depth of penetration of aminolevulinic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive rate after infant doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMC after infant doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: positive rate after booster dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMC after booster dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients achieving Clinical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thirty Day Overall Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of lung and systemic postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnosis of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean pad weight gain (PWG) change of >50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in annualized height velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BADDS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of retrieved oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of mature or metaphase II (MII) oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oocyte recovery ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of trichoscopic findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-adolescent General Communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Percentage of Subjects With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Level of Sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity criteria evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in patient reported outcome measures
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Significant Reflux Esophagitis, Los Angeles grade (≥grade B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in subjective Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HCV Viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Function Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from arrhythmic events to time of physician notification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from activated events to time of physician notification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areolar Dilation of up to 6mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of TUFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of total IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients eligible for surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Opioid Craving Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects With Anti-HBs Antibody Concentration ≥ 100 mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Weight-bearing mechanical axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival and Transfer from NICU
Endpoint domain: Mortality/survival
Primary endpoint: Microbiological Eradication of Ureaplasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: histological activity of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombus size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of chest compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuance of chest compression - cause and time interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ambulatory 6 Minute Walk Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Artery Pressures (Systolic, Diastolic, Mean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Grade ≥2 Laboratory Parameter AEs
Endpoint domain: Adverse events/effects
Primary endpoint: level of mRNA expression of DAP12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bone Strength Index of the Distal Tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Skin toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change of family function
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Eyberg Child Behavior Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sutter-Eyberg Student Behavior Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent Daily Report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Post-Operative Clinical Interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: hemoglobin variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Clinical Recurrence of Crohn's Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in plasma systemic and gut inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Determination of GLP-2 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gut inflammatory markers: Calprotectin, zonulin, and IgA in fecal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Quality of Life- PROMIS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of subjects achieving LDL-C target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of usual biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of experimental biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycaemic shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cancer Patient Fatigue Experiences
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Dose Limiting Toxicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall patient cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of major adverse cardiac events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Numerical Rating Scale (NRS) for Pain Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Opioid Use Change From Baseline
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Fecal Microbiome Shannon Diversity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of Cardiac death or Target-vessel myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Rates of Major adverse cardiac and cerebrovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Teachers' Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Control of breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung function volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of knowledge from Baseline to post-test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in violence against women
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Group Mean Change on the Tool of Parenting Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Group Mean Change on the Parenting Practices Interview Harsh Parenting Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Group Mean Change on the Parenting Practices Interview Inept Parenting Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Group Mean Change on the Parenting Practices Interview Prosocial Parenting Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success rate of intubation at first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients who complete the rehabilitation program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Stimulated C-peptide Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: BORG
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Brain activity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behavioral measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Feasibility of holographic technology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence of intracranial hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in central corneal thickness/corneal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organs dysfunction free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of ischemic stroke related to target vessels
Endpoint domain: Mortality/survival
Primary endpoint: NIHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: mRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Pathologic Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Peak Plantar Flexion Moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Step Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Gross Resection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum international normalized ratio (INRmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in heart rate from resting after a 9-minute exercise treadmill test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of arrhythmic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Return to school after surgery
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Local tolerance assessment of cornea and conjunctival sac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of VO2 peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dietary fatty acid uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: whole body inter-organ partitioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Hemoglobin A1c (A1C) From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes on insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes on carbohydrate profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Any Grade 3 Solicited Local Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: latency of visually evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of reaching euvolemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of the van der Heijde modified Sharp score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of AMG 510
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 510
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time Zero to Infinity (AUCinf) of AMG 510
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Defect volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC 0→∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3D gait analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained virological response (SVR) at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in mean glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the concentration-time curve (AUC) 0-24hr of plasma glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety assessed by Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Upper Respiratory Tract Infections (URTI)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adhesions on cineMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactogenicity of the vaccine regimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAI (hemagglutination inhibition) titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Granzyme B levels and Interferon gamma to interleukin 10 ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of composite of overall death and spontaneous myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Combined Counts of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of index cases referring partners
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Freedom from AF and/or ATs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Percent of Myocardial Infarction Size to the Fraction of Left Ventricular Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hair caliber diameter and hair counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes